EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SonoScape Medical Corp (300633) fair value: what the stock is really worth

As of Sep 22, 2026: fair value of SonoScape Medical Corp ¥12.64, price ¥19.85, upside -36.3%, quality 55 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · CN · ISIN CNE100002P91

SM Some data Sep 24, 2026

SonoScape Medical Corp

300633 · SHE

Stretched ValuationStrong overvaluation with only moderate quality.

!Fair value ¥12.64 · Strongly overvalued (−36%)
!Quality 55/100
!Expensive Growth (revenue 5y +14.7 %/yr)
!Thin margins · 7.5% net margin (TTM)
!Low debt · negative free cash flow
·0.91% dividend yield
!Mixed vs. peers (6/13)
!Narrow moat 32/100
!Evidence only medium, so the estimate is less certain
!Weak on past: 22 out of 100
!Weak on dividend: 18 out of 100
Watch SonoScape Medical Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥59.72 ¥17.97 Fair Value ¥12.64 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range ¥17.97 – ¥59.72 · fair‑value band ¥10.69 – ¥15.30 · the ¥19.85 price screens above the ¥12.64 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.

Follow SonoScape Medical in your weekly email

Every Wednesday you see whether SonoScape Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally.

Show more

SonoScape Medical Corp., together with its subsidiaries, engages in the research, development, production, and sale of medical diagnosis and treatment equipment in China and internationally. It offers ultrasound medical imaging products comprising trolley and portable color dopplers, B/W ultrasounds, and transducers; endoscopic diagnosis and treatment products consisting of image processors, light sources, gastroenterology and pulmonology products, endoscopic ultrasound, duodenoscopes, and peripheral equipment; minimally invasive surgery solutions, such as camera systems and flexible endoscopes; veterinary ultrasound and endoscopy solutions; and intravascular intervention products. The company also provides face-to-face and online training for ultrasound and endoscopy systems; technical and spare parts support; preventive maintenance, calibration, breakdown repair, and other field services; and upgrade services. In addition, it is involved in the software industry. SonoScape Medical Corp. was incorporated in 2002 and is headquartered in Shenzhen, China.

Stock analysis

SonoScape Medical Corp (300633) currently trades at ¥19.85, while our model-based Fair Value estimate is ¥12.64, implying the stock looks roughly 57.1% overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of ¥10.40 per share, and 0 of the 15 models we run sit above the ¥19.85 price.

Bear case: the Asset-Based group reads lowest at ¥5.15, and 15 of the 15 models stay below the price. Evidence for this calculation is medium.

Scenario range: ¥10.69 (bear) to ¥15.30 (bull), the price of ¥19.85 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

SonoScape Medical Corp reported revenue of 2.3B CNY in FY2025 versus 1.4B CNY in FY2021, a compound +12.4%/yr. Reported net income was 197M CNY in FY2025, compounding −5.5%/yr from FY2021.

Key figures

Market cap 8.6B CNY (≈ $1.3B) · P/E ratio 48.4 · P/S ratio 4.14 · EPS (TTM) ¥0.4100 · Dividend yield 0.9% · Net margin 8.5% · Return on equity 5.6% · Return on assets (EBIT) 7.5%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).

What moves the price

The share trades about 43% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −36%, 300633 screens richer than that median.

Fair Value models

Bear ¥10.69 Fair Value ¥12.64 Bull ¥15.30
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (¥0.1682 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings ¥7.41 ¥10.40 ¥15.13 76
Residual Income ¥5.70 ¥5.74 ¥5.41 76
EPV ¥6.39 ¥6.82 ¥7.17 74
All 15 models by family
DCF Models
Owner Earnings ¥7.41 ¥10.40 ¥15.13 76
Earnings-Based
Graham-Dodd ¥3.16 ¥15.79 ¥21.79 64
Lynch FV ¥4.27 ¥6.10 ¥7.93 61
PEG = 1.0 ¥4.27 ¥6.10 ¥7.93 57
EPV ¥6.39 ¥6.82 ¥7.17 74
Multiples
P/E Multiple ¥7.66 ¥10.22 ¥12.77 63
P/S Multiple ¥5.92 ¥7.89 ¥9.87 58
P/B Multiple ¥5.92 ¥7.89 ¥9.87 55
EV/EBIT ¥8.80 ¥10.65 ¥12.49 66
EV/EBITDA ¥10.36 ¥12.73 ¥15.10 67
EV/Revenue ¥7.22 ¥8.91 ¥10.60 54
Asset-Based
NCAV (Graham) ¥3.84 ¥5.15 ¥7.68 54
Economic Profit
Residual Income ¥5.70 ¥5.74 ¥5.41 76
ROIC Compounder ¥6.39 ¥6.82 ¥7.17 72
Growth Earnings
Growth-Adj P/E ¥6.69 ¥9.55 ¥12.42 67

Open the full fair value analysis →

Notify me when 300633 reaches fair value

Put 300633 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 55/100

Of which business quality 55 · Market factors (momentum, volatility) 34

Profitability 41
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 4
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 70
Disciplined investing over empire-building
Low Volatility 77
Calm price path (market factor)
Momentum 22
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 77
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.7%
Start year 2020 (pandemic). Over 10 years: +12.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+1.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.9%
Dividend (yield on the price)0.9%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.1% vs 2%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−4% → 8%
Start year 2020 (pandemic)

300633 screens 57% overvalued. Compare with Abbott Laboratories, →

Compare SonoScape Medical Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 361 stocks

Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 55 · Above median
Fair Value upside −36% · Below median
Profitability
Return on equity (TTM) 6% · Above median
Return on assets 2% · Above median
Net margin (TTM) 8% · Above median
Operating margin (TTM) 1% · Below median
Growth and dividend
Revenue growth 12% · Above median
Dividend yield (TTM) 0.9% · Bottom 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/E (TTM) 48.4× · Priciest 25%
P/B 2.63× · Pricier than median
P/S (TTM) 3.64× · Pricier than median
EV/EBITDA 34.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 11
FUTURE (revenue growth)59 · sector 31
PAST (return on equity)22 · sector 8
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)18 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.69 $74.79 −28%
Stryker Corporation SYK $275.09 $302.60 +10%
Medtronic plc MDT $90.77 $65.57 −28%
Boston Scientific Corporation BSX $44.92 $49.41 +10%
Edwards Lifesciences Corporation EW $88.78 $82.04 −8%
Siemens Healthineers AG SHL €37.43 €35.22 −6%
DexCom, Inc DXCM $89.53 $98.48 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SonoScape Medical Corp · Fair Value
¥12.64 −57%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SonoScape Medical Corp Fair Value". https://www.fairvalue-calculator.com/stock/300633

Frequently asked questions

Is SonoScape Medical Corp (300633) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ¥12.64 versus a price of ¥19.85, about −36% upside (overvalued).
What is the fair value of 300633?
Our model-based fair value for SonoScape Medical Corp is ¥12.64 (as of Sep 24, 2026), built from audited fundamentals. The current price: ¥19.85.
What is the quality score of 300633?
SonoScape Medical Corp has a Quality Score of 55/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SonoScape Medical Corp (300633)?
Our model-based price target is the fair value of ¥12.64 (as of Sep 24, 2026) from 15 valuation models. Cautious scenario ¥10.69, optimistic scenario ¥15.30. It is a calculation from audited fundamentals, not an analyst target.
What is the SonoScape Medical Corp stock forecast for 2026?
Our models put fair value at ¥12.64, about −36% upside versus a price of ¥19.85 (overvalued). Cautious scenario ¥10.69, optimistic scenario ¥15.30. The calculation is refreshed regularly with new filings.
What is the revenue of SonoScape Medical Corp (300633)?
SonoScape Medical Corp reported trailing-twelve-month revenue of about 2.4B CNY (latest available figure, as of Sep 24, 2026).
Does SonoScape Medical Corp pay a dividend?
SonoScape Medical Corp currently shows a dividend yield of about 0.91% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of SonoScape Medical Corp (300633)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SonoScape Medical Corp it is ¥12.64 per share (as of Sep 24, 2026), against a price of ¥19.85. It is the blended result of 15 valuation models (cash flow, earnings, asset, dividend).
Is SonoScape Medical Corp stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 300633 trades above its calculated fair value: price ¥19.85, fair value ¥12.64, a gap of about −36% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300633?
No. The price is what the market pays today (¥19.85); the fair value is what the company's own numbers justify (¥12.64). For SonoScape Medical Corp the two are ¥7.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is SonoScape Medical Corp worth?
The market values SonoScape Medical Corp at about 8.6B CNY (market capitalisation, as of Sep 24, 2026). Per share that is ¥19.85; our models calculate a fair value of ¥12.64 per share.
What do the bullish and bearish scenarios say about 300633?
Our models span a range for SonoScape Medical Corp: cautious scenario ¥10.69, base ¥12.64, optimistic ¥15.30 per share (as of Sep 24, 2026, price ¥19.85). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 300633?
SonoScape Medical Corp trades at a price-to-earnings ratio of 48.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥12.64 is built from several models across several years. Other multiples: P/B 2.6, P/S 3.6, EV/EBITDA 34.1.
How solid is the balance sheet of SonoScape Medical Corp (300633)?
Balance-sheet figures for SonoScape Medical Corp (as of Sep 24, 2026): return on equity 5.6%, debt of 0.01 per unit of equity. They feed the Quality Score of 55/100, which measures business quality independently of the share price.
How far is 300633 from its 52-week high?
SonoScape Medical Corp trades at ¥19.85, about 43% below its 52-week high of ¥34.75 and 10% above the low of ¥17.97 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of ¥12.64 is for.
Which stocks are comparable to SonoScape Medical Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SonoScape Medical Corp stock attractive at the current price?
The data as of Sep 24, 2026: price ¥19.85, calculated fair value ¥12.64 (−36%), Quality Score 55/100, from 15 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300633 calculated?
We run SonoScape Medical Corp through 15 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥12.64, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. SonoScape Medical Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SonoScape Medical Corp (300633)?
The closing price on Sep 22, 2026 was ¥19.85. Our model-based fair value is ¥12.64, about −36% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SonoScape Medical Corp right now?
The price sits above even our optimistic bull case (¥15.30). The favourable scenario is already priced in. Solid but not exceptional quality (55/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of SonoScape Medical Corp (300633) come from?
Earnings per share at SonoScape Medical Corp grew +11.3 % a year from 2013 to 2024. Broken into its drivers: revenue per share +11.0 %, EBIT margin +2.6 %, tax rate +1.4 %, residual (interest, one-offs) −3.6 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of SonoScape Medical Corp

How large is the market capitalisation of SonoScape Medical Corp (300633)?
The market capitalisation of SonoScape Medical Corp is 8.6B CNY (≈ $1.3B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SonoScape Medical Corp (300633)?
The price-to-sales ratio of SonoScape Medical Corp is 4.14 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of SonoScape Medical Corp (300633)?
Earnings per share at SonoScape Medical Corp are ¥0.4100 (price ÷ EPS = P/E 48.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of SonoScape Medical Corp (300633)?
The dividend yield of SonoScape Medical Corp is 0.9% (payout 43.9%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of SonoScape Medical Corp (300633)?
The net margin of SonoScape Medical Corp is 8.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SonoScape Medical Corp (300633)?
The return on equity (ROE) of SonoScape Medical Corp is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SonoScape Medical Corp (300633)?
On an EBIT basis the return on assets of SonoScape Medical Corp is 7.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SonoScape Medical Corp (300633)?
The operating margin of SonoScape Medical Corp is 0.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SonoScape Medical Corp (300633)?
Revenue at SonoScape Medical Corp is growing +11.8% versus a year earlier (3y avg +9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at SonoScape Medical Corp (300633)?
Earnings per share at SonoScape Medical Corp are growing +404% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does SonoScape Medical Corp (300633) generate?
The free cash flow of SonoScape Medical Corp is −190M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does SonoScape Medical Corp (300633) hold?
SonoScape Medical Corp holds more cash than debt, 1.2B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch SonoScape Medical Corp in the live analysis

One click puts SonoScape Medical Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.